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Streptococcus pneumoniae causes life-threatening meningitis. Its capsular polysaccharide determines 
the serotype and influences disease severity but the mechanism is largely unknown. Due to evidence 
of elevated cytokines levels in the meningeal inflammatory response, we measured 41 cytokines/
chemokines and growth factors in cerebrospinal fluid (CSF) samples from 57 South African meningitis 
patients (collected in the period 2018–2019), with confirmed S. pneumoniae serotypes, using a 
multiplexed bead-based immunoassay. Based on multivariable Bayesian regression, using serotype 
10A as a reference and after adjusting for HIV and age, we found IL-6 concentrations significantly 
lower in patients infected with serotypes 6D (undetectable) and 23A (1601 pg/ml), IL-8 concentrations 
significantly higher in those infected with 22A (40,459 pg/ml), 7F (32,400 pg/ml) and 15B/C (6845 pg/
ml), and TNFα concentration significantly higher in those infected with serotype 18A (33,097 pg/
ml). Although a relatively small number of clinical samples were available for this study and 28% of 
samples could not be assigned to a definitive serotype, our data suggests 15B/C worthy of monitoring 
during surveillance as it is associated with in-hospital case fatality and not included in the 13-valent 
polysaccharide conjugate vaccine, PCV13. Our data provides average CSF concentrations of a range 
of cytokines and growth factors for 18 different serotypes (14, 19F, 3, 6A, 7F, 19A, 8, 9N, 10A, 12F, 
15B/C, 22F, 16F, 23A, 31, 18A, 6D, 22A) to serve as a basis for future studies investigating host–
pathogen interaction during pneumococcal meningitis. We note that differences in induction of IL-8 
between serotypes may be particularly worthy of future study.
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Streptococcus pneumoniae is a major cause of pneumonia and invasive pneumococcal diseases (IPD) including 
life-threatening meningitis. An important virulence factor of the pneumococcus is its capsular polysaccharide 
(CPS). The CPS determines the serotype, is used for the manufacture of pneumococcal vaccines and plays a role 
in  IPD1. Vaccines have reduced the burden of disease but protect only against a handful of the approximately 100 
known circulating serotypes. As a result of vaccination, changes in the prevalence of the different serotypes has 
occurred, particularly an increase in those not included in the  vaccines2–4. In addition, the odds ratio of causing 
invasive disease differs between  serotypes5,6 and when IPD does occur, different serotypes have been observed 
to be responsible for different levels of disease  severity7–13. A meta-analysis of disease severity by risk of death 
from IPD indicates that disease severity is a stable serotype-associated property, at least in the pre-PCV  era14.
How the CPS affects disease severity is unclear. It has been suggested that the CPS can influence growth of 
the  pneumococcus15,16 and that there are differences between serotypes in the ability to build a thick capsule. 
Both of these factors have been described both in vitro15 and in vivo17. Clearly though, the ability to cause severe 
disease is not only dependent on capsule size and bacterial growth but also on host–pathogen interactions, pre-
existing immunity and the host immune response towards the different pneumococcal serotypes. Several studies 
suggest levels of cytokines such as interleukin (IL)-6, IL-8, IL-10, IL-1β and tumor necrosis factor (TNF)-α to 
be prognostic for the outcome of bacterial  meningitis18 and certain pneumococcal serotypes have been associ-
ated with higher patient case-fatality ratios in large-scale epidemiological  studies19. Cytokines and chemokines 
released during the host immune response function to not only recruit innate and adaptive immune cells but 
also promote inflammation and therefore play an important role in pneumococcal pathogenesis. Thus, it could 
be hypothesized that the invading pneumococcal serotype influences cytokine concentrations and profiles and 
that these could affect both disease severity and patient outcome (long-term sequelae and survival).
Interleukin-8 (IL-8) for example, has been noted by several studies to be an important player in the patho-
genesis of pneumococcal  diseases18,20–23 but in depth studies on the expression of IL-8 and other human inflam-
matory responses towards different pneumococcal serotypes and the resulting patient outcome, especially in 
meningitis cases, are scarce. Most are limited to animal models, to only a few markers and/or in the number 
of serotypes which are compared. This is likely due to the challenges of assessing the large number of known 
circulating serotypes within one study. Another reason may be the limited access to patient cerebrospinal fluid 
(CSF) samples to measure cytokines, to patient information and/or the difficulty of setting up experiments to 
analyze patient samples while considering all possible confounding factors. Despite these difficulties, an in depth 
understanding of the mechanisms by which pneumococcal serotypes cause differences in disease severity will 
be important to guide and improve future vaccine and treatment designs.
In this study we provide the average concentrations of 41 cytokines and growth factors produced in response 
to 18 different serotypes in patients with laboratory-confirmed pneumococcal meningitis. We aimed to determine 
the relationship between pneumococcal serotypes and (1) the inflammatory profile in residual CSF of South 
African patients with laboratory-confirmed pneumococcal meningitis and (2) the severity of disease (measured 
by in-hospital outcome) to establish whether serotypes associated with a high case-fatality ratio (CFR) in a time 
of routine PCV vaccination, also cause a distinct inflammatory reaction from the host which in turn affects the 
severity of disease. We highlight the difficulties, but also the advantages and insights, that our approach may 
bring, as a basis for the planning of future large-scale studies.
Methods
Study population. The study population included patients of all ages enrolled in the South African GERMS-
SA enhanced surveillance study from January 2018 to August 2019, with laboratory-confirmed pneumococcal 
meningitis diagnosed from a lumbar puncture performed by the attending doctor. Samples were collected dur-
ing the period where routine PCV13 vaccination of infants in a 2 plus 1 schedule was established. South Africa 
introduced the 7-valent PCV in 2009 and in 2011 PCV7 was replaced by PCV13.
The GERMS-SA programme (http:// www. webdev. nicd. ac. za/ index. php/ germs- sa/) is an active laboratory-
based surveillance programme for which information on bacterial and fungal pathogens, including Streptococcus 
pneumoniae, is collected. We chose 10 sentinel surveillance sites from provinces across South Africa (Eastern 
Cape, Free State, Gauteng, Kwazulu-Natal, Mpumalanga, North West and Western Cape) which had more than 
10 cases of laboratory-confirmed pneumococcal meningitis cases with CSF available and cultured specimen in 
both 2014 and 2015. All sites chosen were part of the enhanced surveillance for which detailed patient informa-
tion was available. Informed consent for analysis of CSF was collected from patients and/or guardians for both 
collection of data and analysis of residual CSF. Due to ethical reasons relating to the collection of CSF samples 
from healthy patients a control group was not included in this study. All research was performed in accordance 
with the relevant guidelines and regulations.
Ethics. The GERMS-SA surveillance study was approved by the Human Research Ethics Committee (Medi-
cal), University of Witwatersrand (clearance numbers M140159, M081117, M021042) and additional permission 
for this study was granted by the Human Research Ethics Committee (Medical), University of Witwatersrand 
(clearance number M180101). Where required, approval was granted by provincial and university ethics com-
mittees (Clearance numbers: Free state 230,408–011 / 180/09A; Kwazulu-Natal BF130/11 and HRKM024/09; 
Western Cape REC REF 115/2009, N04/01/001). Permission for analysis of data in Switzerland was obtained 
from the Cantonal Ethics Commission Bern (Kantonale Ethikkommission für die Forschung, KEK, Bern, Pro-
ject Number 2018–01,172).
Sample collection and storage. Routine CSF sample collection and analysis is as follows. CSF patient 
samples were collected at the request of the attending clinician. After completion of diagnostic procedures any 
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residual CSF was collected by the site surveillance officers if the presence of S. pneumoniae was confirmed by 
the local laboratory. Normal diagnostic procedures in all laboratories include microscopy (cell count and Gram 
stain), chemistry (protein, glucose and sodium levels), culture and antimicrobial susceptibility of any pathogen 
isolated. Where a raised white cell count and/or Gram-positive lanceolate diplococci were seen on Gram stain, 
a rapid antigen detection test is performed to confirm the presence of pneumococcal antigen. Pneumococcal 
isolates and/or residual CSF samples are then routinely submitted to the National Institute for Communicable 
Diseases (NICD) in Johannesburg, South Africa where full identification is carried out to confirm the species 
and serotyping of isolates by Quellung and polymerase chain reaction (PCR) is also performed. Real time-PCR 
(RT-PCR) for lytA gene detection is routinely performed on all samples, followed by a multiplex serotype PCR 
if  positive24. The multiplex PCR detects and confirms 38 different pneumococcal serotypes and any samples that 
were not one of these 38 were called NEG38.
For this study, surveillance officers were given a standard operating procedure for the collection of CSF 
samples for this study. They were requested to store the residual CSF samples on site until further transport (at 
−20 °C or −80 °C depending on availability of equipment). The residual CSF samples were then transported 
from sentinel site laboratories of collection to the NICD. To avoid unnecessary freeze–thaw cycles all samples 
were transported on dry ice and immediately stored at −80 °C upon arrival at the NICD until further multiplex 
analysis. Of 860 pneumococcal meningitis patients at the selected sentinel sites during the study period, from 
whom CSF was collected for diagnostic purposes, 76 residual CSF samples were available for collection and 
analysis for this study. 12 samples had insufficient residual CSF (minimum 200 µl required) to perform multi-
plex analysis and were thus excluded from analysis. All samples were analyzed within 1 year of collection. After 
multiplex analysis, 5 samples were excluded due to time between collection and freezing of sample exceeding 
48 h. Another 2 samples were excluded because upon follow-up it was confirmed that the infecting agent was 
not S. pneumoniae. Specimens which were NEG38, serotypes included in pool G (29, 34, 35, 42 and 47) and 
those which were not distinguishable (PCR positive but not distinguishable between individual serotypes) were 
grouped into "undefined non-vaccine serotypes". A total of n = 57 samples was included in the final analysis. 
Serotype 10A served as the reference serotype as it has previously been described as having an intermediate case 
fatality  rate13 and has also previously been associated with increased risk of meningitis in different studies (sum-
marized  in19). In the present study, of the two patients with serotype 10A, one case was fatal and one survived. 
Serotypes of samples with missing outcome information included: 19F (n = 1), 3 (n = 1), 9 N (n = 1), 22F (n = 1), 
6D (n = 1), 22A (n = 1), and undefined (n = 3). These samples were not included in the analysis of case fatality 
associated with serotype. We did not eliminate these samples from the analysis of inflammatory markers in an 
effort to keep the sample size and serotypes analyzed as large as possible.
Analysis of inflammatory markers. We measured the concentrations of inflammatory markers in CSF 
using 39-plex and 5-plex microsphere-based multiplex assays (Human Custom ProcartaPlex 39-plex cat. num-
ber PPX-39-MX9HJM4 and 5-plex cat. number PPX-05-MXNKR67, Thermo Fisher Scientific, Waltham, MA, 
USA). The 39-plex immunoassay included the following markers: CD40-Ligand, Epithelial-derived neutrophil-
activation protein (ENA)-78 (LIX), Eotaxin, Granulocyte-Colony stimulating factor (G-CSF)/CSF-3, Granulo-
cyte–Macrophage(GM)-CSF, Growth related oncogene (Gro)-α/KC, Hepatocyte growth factor (HGF), Inter-
feron (IFN)-α, IFN-γ, IL-10, IL-12p40, IL-13, IL-15, IL-17A, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, 
IFN-γ induced protein (IP)-10, IL-6 family cytokine (LIF), M-CSF, Monocyte chemotactic protein (MCP)-1, 
MCP-3, monokine induced by IFN-γ (MIG), Macrophage inflammatory protein (MIP)-1α, MIP-1β, Plasmi-
nogen activator inhibitor (PAI)-1, Platelet derived growth factor (PDGF)-BB, Resistin, Stem cell factor (SCF), 
TNF-α, TNF-related apoptosis-inducing ligand (TRAIL), Vascular endothelial growth factor (VEGF)-A, Neuro-
trophic growth factor (bNGF) and sFas-Ligand. The 5-plex immunoassay included the following markers: IFN-
γ, IL-17F, IL-6, Transforming growth factor (TGF)-α, TNF-α. The markers were selected based on a previous 
publication which measured immune molecules in human  CSF25 as well as from publications presenting data 
on their function and/or concentrations in inflammation, meningitis and/or CSF. The panels include a range of 
cytokines, chemokines and factors which play key roles in processes reflecting inflammatory pathways, during 
pneumococcal disease and/or which have been reported to be elevated in bacterial meningitis. Key functions of 
the chosen inflammatory markers with references to previous publications are summarized in Supplementary 
Table S1.
The assays were run according to the manufacturer’s instructions. Samples (25 µl) were measured undiluted 
and the standards and CSF samples run in duplicate. The 39-plex immunoassay was prioritized and if enough 
sample remained, the 5-plex immunoassay was additionally performed. This was possible for all except two sam-
ples which contained pneumococcal serotypes 6D and 18A. Beads were acquired on a Bio-Plex 200 instrument 
(Bio-Rad) and the fluorescence signal for 50 beads per analyte measured. The data was analyzed with Bio-Plex 
manager (version 6.1, Bio-Rad) capable of generating a five-parameter logistic (5-PL) curve fit. For statistical 
purposes, a value of zero was assigned to values with concentrations below the lower limit of quantification 
(LLOQ). To include concentrations with values above the upper limit of quantification for (ULOQ) statistical 
purposes, we assigned a new value where the concentration of the highest obtained value of the corresponding 
analyte was taken and a value of + 1000 added. Analyte concentrations are expressed as pg/ml.
Statistical analysis. In-depth Bayesian univariate and multivariable modeling was performed specifi-
cally on IL-6, IL-8 and TNF-α, because both IL-6 and TNF-α are well described cytokines (see supplementary 
Table S1) and IL-8 because concentrations varied greatly between patients (data not shown). We chose Bayesian 
regression modeling to determine which serotypes may be associated with case fatality and varying cytokine 
concentrations. Due to the sample size limitation, a Bayesian framework may be more appropriate than con-
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ventional regression  approaches26 to test for such associations. Due to the high prevalence of HIV amongst the 
South African patients and the known relationship between IPD incidence and HIV  infection27, HIV was con-
trolled for as a confounder. Age was a categorical variable with the following groups: below 5 years (10 samples), 
above or equal to 5 years (42 samples), unknown (5 samples).
Merging and cleaning of sample data and patient data from the GERMS-SA enhanced surveillance data was 
conducted using Stata 16.0 (StataCorp, College Station, Texas, USA). The risk of case fatality was evaluated 
as a function of serotype and associated co-variables via full Bayesian binomial model. Weakly informative 
priors were set by letting parameters follow Student’s t distributions with 7 df, centered on 0 with a scale of 2.5 
(default values). Concentrations of individual cytokines (IL-6, IL-8, TNF-α) were related to explanatory vari-
ables using Bayesian linear multivariable regression with drawing 4000 posterior samples. TNF-α values were 
log-transformed to conform to normality. In each model, a total of four Markov chains were used, each based 
on 1000 transitions using 10 leapfrog steps per transition, a warmup phase of 1000 and further sampling of 
1000 steps. Bayesian regression analyses were conducted using the function stan_glm (Bayesian Generalized 
linear modeling) available in the R package rstanarm28. To ensure valid inferences, convergence to the target 
distributions of the Markov chains (the independent Markov chains were initialized with diffuse starting values 
for the parameters and were sampled until all values for Rhat were below 1.1) was checked. Effective Samples 
Size (ESS) for each estimated parameter were all above 1000, which is largely above what is recommended for 
applied regression  analyses28.
Results
A total of 57 samples were included in the final analysis. Amongst those with known gender information, 46% 
(24/52) were female. For those with available HIV status, 79% (34/43) were positive. Of those with available 
age information the age range was 0 to 69 years and the three most represented age groups were patients aged 
25–44 years (25/52, 44%), 45–64 years (10/52, 18%) and those aged < 1 year (8/52, 14%). The three most common 
serotypes were serotype 8 (7/57, 12%), serotype 3 (5/57, 9%) and serotype 12F (5/57, 9%). Of the 18 serotypes 
identified, five were PCV serotypes: serotypes 3, 6A, 7F, 14 and 19A, but of these only serotype 3 was represented 
in more than 5% of the samples. Isolates/specimens which were non-typable, included in the pool G serotypes, 
or undistinguishable, together made up 28% (16/57) of the cases. Of the cases with available outcome informa-
tion (17/48, 35%) had a fatal outcome (Supplementary Table S2). Detailed Bayesian statistics was performed 
on three cytokines with key roles in inflammation in bacterial meningitis: IL-6, IL-8 and TNFα. We did not 
perform detailed Bayesian statistics on all inflammatory markers to avoid increasing the risk of family-wise 
error due to multiple testing. However, concentrations per serotype of all inflammatory markers can be found 
in Supplementary Table S3. Overall, the analysis of cytokine concentrations indicated that CSF from meningitis 
patients with serotypes 6D and 23A had low levels of IL-6 whereas those with serotypes 22A, 7F and 15B/C had 
high levels of IL-8 and with serotype 18A had high concentrations of TNFα.
Univariate and multivariable analysis of IL-6 concentration between different serotypes. On 
multivariable analysis controlling for age and HIV status and compared to serotype 10A, serotype 6D (coeffi-
cient [coef]: −12,712.82, highest density interval lower to upper bound [HDI]: −22,977.67, −2514.49) and 23A 
(coef: -10,979.91, HDI: −19,201.69, −2869.32) were associated with lower levels of IL-6 in the CSF of meningitis 
patients (Fig. 1A, Supplementary Table S4, Bayesian  R2 = 0.44). On univariate analysis and compared to menin-
gitis patients infected with serotype 10A, those infected with 6D, 23A, 6A, 16F and 3 were associated with lower 
levels of IL-6 concentrations in the CSF (Fig. 1A, Supplementary Table S4). The group of "undefined serotypes" 
including those non-typable, not distinguishable by PCR and those in pool G were significantly associated with 
a lower IL-6 concentration on univariate analysis but not on multivariable analysis.
Univariate and multivariable analysis of IL-8 concentration between different serotypes. On 
multivariable analysis controlling for age and HIV status and compared to serotype 10A, serotypes 22A (coef: 
26,090.77, HDI: 2389.31, 48,894.44), 7F (coef: 23,255.71, HDI: 1374.87, 44,902.99) and 15B/C (coef: 17,050.5, 
HDI: 614.6, 33,345.73) were associated with higher levels of IL-8 in the CSF of meningitis patients (Fig. 1B, 
Bayesian  R2 = 0.44, Supplementary Table S5). Serotypes significantly associated with higher levels of IL-8 in CSF 
compared to 10A on univariate analysis were serotypes 22A, 7F, 23A and 12F (Fig. 1B, Bayesian  R2 = 0.44, Sup-
plementary Table S5). Although serotype 6D had noticeably lower levels of IL-8 (Supplementary Table S3), this 
was not significant on either univariate or multivariable analysis (Fig. 1B, Supplementary Table S5).
Univariate and multivariable analysis of TNFα concentration between different sero-
types. Compared to serotype 10A, on multivariable analysis controlling for age and HIV status, we found 
serotype 18A to be associated with higher concentration of TNFα concentration (coef: 6.22, HDI: 2.08, 10.31) 
in the CSF of meningitis patients (Fig. 1C, Bayesian  R2 = 0.40, Supplementary Table S6). We observed a lower 
TNFα concentration in the meningitis patient infected with serotype 6D (Supplementary Table S3) which was, 
however, not significant upon univariate and multivariable analysis (Fig. 1C, Supplementary Table S6). We did 
not see any pattern between serotypes associated with case fatality and cytokine concentrations.
Univariate and multivariable analysis of case fatality measured by in-hospital outcome 
between different serotypes. Using Bayesian statistics, compared to serotype 10A (1 out of 2 fatal) on 
a univariate but not multivariable analysis of serotypes associated with case fatality (in-hospital outcome), we 
found serotype 15B/C (3 of 3 fatal) to be significantly associated with case fatality (coeff 2.94, HDI: 0.34–7.35) 
(Fig. 2 Bayesian  R2 = 0.28, Supplementary Table S7). No other serotypes were significantly associated with case 
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fatality compared to serotype 10A. Apart from serotype 15B/C, serotypes which showed a trend towards being 
associated with case fatality on both uni- and multivariable analysis were serotypes 19A, 22F, 6A and 3. Serotypes 
8, 7F, 19F, 9 N and 14 showed a trend towards being less associated with case fatality compared to 10A.
Discussion
We hypothesized that serotypes associated with severe disease would cause a strong inflammatory reaction, 
and therefore high concentrations of inflammatory cytokines especially IL-6, IL-8 and TNFα compared to sero-
types associated with less severe disease. To test this, we looked for an association of serotype with case fatality. 
Due to the small sample size (n = 57), we opted for Bayesian regression analyses instead of classical frequentist 
approaches and found serotype 15B/C to be significantly associated with case fatality in our cohort. In descending 
order, we found serotypes 15B/C, 19A, 22F, 6A and 3 to show a (non-significant) trend towards being associated 
with case fatality compared to 10A. This is similar to previous publications which also found these serotypes 
associated with either severe disease and/or a higher  CFR19. We also see serotype 15B/C being associated with 
case fatality in a large epidemiological study including all IPD cases in all ages in the vaccine era (2012–2018) 
which we have conducted (manuscript in preparation). These findings further support the association between 
15B/C and case fatality in this study. Based on this conclusion, and in combination with knowledge from previous 
publications we hypothesized that especially serotypes 15B/C, 19A, 6A and 3 would cause a strong inflammatory 
reaction with high concentrations of IL-6, IL-8 and TNFα.
We were able to determine differences in the average concentration of 41 different inflammatory markers in 
the CSF of pneumococcal meningitis patients infected with different serotypes (14, 19F, 3, 6A, 7F, 19A, 8, 9N, 
10A, 12F, 15B/C, 22F, 16F, 23A, 31, 18A, 6D, 22A) in a period of established PCV13 vaccination. We found that 
compared to meningitis patients infected with serotype 10A, the CSF concentration of IL-6 was significantly 
lower in those infected with 23A and 6D, the IL-8 concentration was significantly higher in those infected with 
22A, 7F and 15B/C; and the TNFα concentration was significantly higher in those infected with serotype 18A. 
Concentrations of other inflammatory markers (especially ENA-78, G-CSF/CSF-3, Gro-α/KC, HGF, IFN-γ, 
IL-10, IL-1β, IP-10, LIF, M-CSF, MCP-1, MIG, MIP-1α, MIP-1β, PAI-1, Resistin, and VEGF-A) varied greatly 
between patients. A distinct inflammatory profile of serotypes associated with severe disease remains to be 
determined in a larger study.
In line with our hypothesis, we found serotype 15B/C to be significantly associated with a higher IL-8 con-
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Figure 1.  Serotypes associated with varying concentrations of (A) IL-6, (B) IL-8 and (C) TNF-α in 
cerebrospinal fluid (South African meningitis patients, 2018–2019). The 90% highest density intervals (HDI) of 
the posterior distributions of the estimated regression coefficients (β) are depicted as horizontal bars and dots 
indicate their medians, for both unadjusted (upper bars) and adjusted (lower bars; covariables HIV status and 
patient age) full Bayesian multivariable linear regression models. Serotypes are sorted from top to bottom in 
decreasing risk of case fatality. Serotype 10A was chosen as ad-hoc reference, for which β was set to 0. TNF-α 
concentrations were log-transformed to conform to normality prior to analysis. n = 57. This figure was generated 
using R (R Core Team (2019)). R: A language and environment for statistical computing. R Foundation for 
Statistical Computing, Vienna, Austria. https:// www.R- proje ct. org/).
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meningitis patients infected with other serotypes including those previously associated with case fatality and/or 
severe disease, to be significantly different to those infected with serotype 10A. IL-6 is an acute phase response 
 cytokine29. It is possible that the CSF samples were taken after the peak of the IL-6 response and differences 
between serotypes missed. Contrary to our expectation, we also found serotype 7F to be associated with relatively 
high levels of IL-8. Serotype 7F is described as highly invasive rather than a common colonizer and in a previ-
ous in vivo experiment caused less severe disease than serotype  6B17. IL-8 is an important chemoattractant for 
neutrophils in humans and has been shown to play a role in the pathogenesis of pneumococcal  disease18,20–22,30,31. 
Two in vitro studies describe pneumolysin as a factor influencing the IL-8  concentration20,32 while two other 
studies (in vitro and in vivo) describe NanA (a sialidase expressed by pneumococci) to contribute to changes 
in IL-8  concentrations21,33. Both these mechanisms may also contribute to the varying amounts of IL-8 which 
we see between patient samples. That the serotype influences the host IL-8 concentration was also observed in 
another  study34. The latter study was limited to three serotypes (1, 3 and 9V) and our results confirm and extend 
these results with additional serotypes. Overall, although a larger study would be required to confirm the effect 
of serotype on the secretion of IL-8 (as well as IL-6 and TNFα) and on patient outcome, we did find that IL-8 
differed significantly between more than two serotypes. Whether changes in IL-8 concentrations are related to 
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Figure 2.  Serotypes associated with higher case fatality risk (South African meningitis patients, 2018–2019). 
The 90% highest density intervals (HDI) of the posterior distributions of the estimated regression coefficients 
(β) are depicted as horizontal bars and dots indicate their medians, for both unadjusted (upper bars) and 
adjusted (lower bars; covariables HIV status and patient age) full Bayesian multinomial logit models. Serotypes 
are sorted from top to bottom in decreasing risk of case fatality as compared to the case fatality rate of the 
ad-hoc reference serotype 10A, for which β was set to 0. n = 57. This figure was generated using R (R Core Team 
(2019)). R: A language and environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria. https:// www.R- proje ct. org/).
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as mentioned  in35) or other bacteria factors, such as haemolytic activity of pneumolysin or other virulence factors 
as described above, remains to be determined.
We faced two very important challenges in this study, both of which show the complexity and difficulties of 
setting up a study such as this. The first and in our opinion the most important, was that we were only able to 
collect a small number of samples per serotype. This means (1) we cannot rule out the effect of the host genetic 
background as well as other confounding factors on the reaction towards pneumococcal serotypes, (2) that we 
may have a selection bias and are missing serotypes for which samples were not collected and (3) that we cannot 
yet make final conclusions about differences of cytokine concentrations caused by different serotypes. However, a 
strength of this study is that, instead of using frequentist statistics which are often based on maximum likelihood 
estimation and often offer insufficient power with small sample sizes, we used a Bayesian statistical framework 
with weak priors, to better quantify the amount of information in the  data26,36. A second important challenge 
was that we were not able to control the time point of CSF collection or how the samples were processed. CSF 
samples are difficult to obtain, both ethically and logistically. A big advantage of this study was that we obtained 
residual CSF from lumbar punctures routinely performed for diagnosis from patients already enrolled in the 
GERMS-SA surveillance programme. This allowed us to perform analysis on samples for which clinical data was 
available and meant there was no additional suffering for the patient due to CSF collection. The disadvantage of 
this is that the concentrations measured indicate the inflammatory marker concentrations upon patient admis-
sion and this may be a different time point in disease for each patient. In any future studies it will be necessary 
to rule out the effect of the host genetic background by increasing the sample size to include hundreds of CSF 
samples as well as addressing other mentioned challenges above. Future studies would also benefit from the col-
lection of blood samples at the same time as CSF. Implementing all of these suggestions will be challenging for 
a single study and therefore may be addressed by multiple smaller studies analyzing each one of these aspects.
In conclusion, we were able to determine the concentrations of 41 inflammatory markers in the CSF of 57 
South African meningitis patients infected with 18 different pneumococcal serotypes in an era of established PCV 
vaccination. We showed that even with a limited sample size, Bayesian statistics is appropriate to gain valuable 
insights and obtain information useful to guide future studies. We aimed to contribute to the pathophysiological 
understanding of pneumococcal meningitis, specifically the relationship between serotype, cytokine levels in the 
CSF and the outcome. We hope that this data will be useful for planning future larger studies, for example for 
power analysis to estimate sample sizes required. The panel of cytokine data should prove useful comparison in 
future studies of pneumococcal meningitis and other inflammatory diseases of the CSF.
We note that serotype 15B/C may be associated with in-hospital case fatality. 15B/C is not a component of 
the current PCV13 vaccine and so we propose that it is of interest in surveillance and future vaccine design. We 
did not find a clear correlation between serotype, in-hospital case fatality and the CSF concentration of IL-6, 
IL-8 and TNFα in CSF of meningitis patients but note that IL-8, which was at a relatively high concentration in 
patients infected with serotype 15B/C, may be of particular interest for future studies.
Data availability
All data generated or analysed during this study are included in this published article and its supplementary 
information files.
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